GreenLight SPAC Presentation Deck

CBH GreenLight influenza vaccine tackles significant current problems Need for greater efficacy and shorter cycle times for seasonal vaccine updates ~$3.3B market Influenza Challenge Mismatch between vaccine strains and circulating seasonal strains due to strain selection occurring ~6 months prior to human dosing The egg-based production process of current influenza vaccines often cause viral mutations that result in reduced efficacy Slow in a pandemic response setting due to inadequate supply of chicken eggs • Typical efficacy is ~40-70% Our Proposed Solution Seasonal influenza vaccine candidates Proprietary RNA manufacturing platform Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Target profile advantages compared to traditional vaccine production ● Shorter cycle time from strain selection to vaccine production due to removal of live pathogen and egg adaptation steps Greater reliability in producing vaccine formulation that matches circulating strain as exact antigen(s) is encoded Timely scalable production in case of pandemic influenza strain is possible ● Potential for higher efficacy with novel antigen design HUMAN HEALTH 52

View entire presentation